Hoffmann & Baron, on Behalf of Aquestive, Inc., Successfully Invalidates All Claims of Orange Book Patent for Valtoco® Nasal Spray in Aquestive Therapeutics, Inc. v. Neurelis, Inc.
Please follow the link for more information:
https://bit.ly/33x08hn
Please view our announcement regarding Hoffmann & Baron's COVID-19 Update & Protocol.
https://bit.ly/2WcoXgn
Hoffmann & Baron has successfully invalidated several patents, asserted against its client, Rimfrost AS, in inter partes review (IPR) proceedings before the Patent Trial and Board (PTAB). As detailed in the attached article, Hoffmann & Baron utilized those earlier successes at the PTAB to help invalidate another patent owned by the same patentee. In particular, the PTAB based its unpatentability decision, in part, on its prior findings, and ruled that the patent owner was collaterally estopped from relying on arguments that were previously rejected by the PTAB.
https://bit.ly/2ONTZGO
HBIPLAW.COM
Hoffmann & Baron’s Defense of Rimfrost Analyzed on Lexology - Hoffmann & Baron, LLP
John Gallagher was featured by Long Island Business News in its annual section entitled “Who’s Who in Intellectual Property Law.”
https://bit.ly/37jjsOI
HBIPLAW.COM
John Gallagher Featured in Long Island Business News - Hoffmann & Baron, LLP
Hoffmann & Baron, LLP proudly supports the American Cancer Society Denim Days 2019!
Hoffmann & Baron Obtains Victories For Rimfrost AS At The Federal Circuit
https://bit.ly/2BLwjfA
U.S. Supreme Court Denies BDSI’s Petition for Certiorari Seeking to Require the U.S. PTAB to Reconsider Decision to Not Institute Inter Partes Reviews of Aquestive’s U.S. Patent No. 8,765,167, as Drafted/Prosecuted/Defended By Hoffmann & Baron
https://bit.ly/34WnVb7
PTAB Confirms Hoffmann & Baron’s Successful Invalidation of All Claims of US Patent No. 9,320,765 on behalf of Rimfrost AS (Rimfrost AS v. Aker Biomarine AS)
https://bit.ly/34xBgX8
